Tobam Has $26,000 Position in Baxter International Inc. (NYSE:BAX)

Tobam lessened its position in Baxter International Inc. (NYSE:BAX) by 94.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 770 shares of the medical instruments supplier’s stock after selling 12,063 shares during the quarter. Tobam’s holdings in Baxter International were worth $26,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Nicholas Hoffman & Company LLC. acquired a new position in shares of Baxter International during the 4th quarter worth approximately $907,000. Bank of New York Mellon Corp raised its holdings in shares of Baxter International by 22.3% during the 4th quarter. Bank of New York Mellon Corp now owns 15,359,040 shares of the medical instruments supplier’s stock worth $447,870,000 after buying an additional 2,803,920 shares in the last quarter. Dodge & Cox raised its holdings in shares of Baxter International by 13.0% during the 4th quarter. Dodge & Cox now owns 50,377,294 shares of the medical instruments supplier’s stock worth $1,469,002,000 after buying an additional 5,779,100 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Baxter International by 40.4% during the 4th quarter. Russell Investments Group Ltd. now owns 1,745,709 shares of the medical instruments supplier’s stock worth $50,904,000 after buying an additional 502,370 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Baxter International by 1.2% during the 4th quarter. Rhumbline Advisers now owns 1,113,125 shares of the medical instruments supplier’s stock worth $32,459,000 after buying an additional 13,424 shares in the last quarter. Institutional investors and hedge funds own 90.19% of the company’s stock.

Baxter International Trading Down 2.4%

Shares of BAX stock opened at $30.60 on Friday. The stock has a market cap of $15.70 billion, a price-to-earnings ratio of -23.91, a PEG ratio of 0.93 and a beta of 0.61. The stock has a 50-day moving average of $30.21 and a 200-day moving average of $31.36. The company has a current ratio of 1.43, a quick ratio of 1.09 and a debt-to-equity ratio of 1.31. Baxter International Inc. has a 1-year low of $26.25 and a 1-year high of $40.49.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.62 EPS for the quarter, beating the consensus estimate of $0.48 by $0.14. Baxter International had a positive return on equity of 16.67% and a negative net margin of 5.05%. The company had revenue of $2.63 billion for the quarter, compared to analyst estimates of $2.59 billion. During the same quarter in the prior year, the company earned $0.65 EPS. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. On average, equities research analysts forecast that Baxter International Inc. will post 2.48 earnings per share for the current year.

Baxter International Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 1st. Investors of record on Friday, May 30th will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Friday, May 30th. This represents a $0.68 annualized dividend and a dividend yield of 2.22%. Baxter International’s payout ratio is -61.82%.

Wall Street Analyst Weigh In

BAX has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lowered their price target on Baxter International from $38.00 to $36.00 and set a “neutral” rating for the company in a report on Friday, February 21st. The Goldman Sachs Group assumed coverage on Baxter International in a report on Wednesday, February 26th. They set a “buy” rating and a $42.00 price target for the company. Argus raised Baxter International from a “hold” rating to a “buy” rating in a report on Monday, February 24th. Wells Fargo & Company lowered their target price on Baxter International from $36.00 to $33.00 and set an “equal weight” rating for the company in a report on Friday, May 2nd. Finally, Morgan Stanley lowered their target price on Baxter International from $30.00 to $28.00 and set an “underweight” rating for the company in a report on Monday, May 5th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $37.25.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.